Health
From The Report: Mexico 2015
View in Online Reader

A decade after the introduction of the Popular Health Insurance Scheme, the national insurance programme, Mexico has made tremendous progress toward attaining universal coverage, albeit limited. The country is now striving to guarantee universal access to health care, not an easy feat for a fragmented system suffering from decades of under-spending. While the sector reform announced by the government in 2013 has taken a backseat in the context of fiscal constraints, steps to increase integration among public institutions and between the public and private sectors continue, as part of a countrywide effort to increase efficiency and curb rising costs. As a result, greater cooperation among public institutions and between the public and private sectors should be expected in the coming years. Meanwhile, as standards of living improve, driving demand for health care services, Mexico will remain a key market in Latin America, providing opportunities for drug and device manufacturers.

This chapter includes interviews with Jose Antonio Gonzalez Anaya, Managing Director, Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS) and Sandra Sánchez y Oldenhage, Director-General, PROBIOMED.

Articles from this Chapter

Overview

Healthy prospects: Cooperation between public and private sectors is increasing
OBG
plus

A decade after the introduction of the Popular Health Insurance Scheme (Seguro Popular de Salud, SPS), the national insurance programme, Mexico has made tremendous progress toward attaining universal coverage, albeit limited. The country is now striving to guarantee universal access to health care, not an easy feat for a fragmented system suffering from decades of under-spending. While the sector reform announced by the government of Enrique Peña Nieto in 2013 has been postponed in the short term,…

Interview

Preventive measures: OBG talks to José Antonio González Anaya, Managing Director, Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS)
OBG
plus

Interview:José Antonio González Anaya In 2014, Mexico experienced the second-largest increase in formal employment since 1997. What were the main causes of this growth? JOSÉ ANTONIO GONZÁLEZ ANAYA:This recent growth in formal employment has centred around manufacturing, although construction picked up in the last six months of the year. What is impressive about the increase was that it was not a “comeback” year after an economic crisis, such as in 1996 or 2010. Additionally,…

Interview

Protecting research: OBG talks to Sandra Sánchez y Oldenhage, Director-General, PROBIOMED
OBG
plus

Interview:Sandra Sánchez y Oldenhage How will new regulations affect biotech companies? SANDRA SÁNCHEZ Y OLDENHAGE: As of December 2014 there is a new set of rules: Regulation 257 was published, affecting biosimilar and biotechnological products in Mexico. This has been a very lengthy process and a controversial one, but one that has resulted in Mexico having a high-standard regulation that is best-in-class within Latin America – and comparable with many European regulatory standards.…

Analysis

A maturing market: Pharmaceuticals companies adjust business strategies to changing market dynamics
OBG
plus

The continued increase in market share of low-cost generics, coupled with the consolidation of purchases by the institutional market led to slower revenue growth in pharmaceuticals for human use in 2014. Nonetheless, the strengthening of Mexico’s regulatory framework is opening up new opportunities. Market Fundamentals Generating annual revenues of around $13bn, Mexico’s pharmaceuticals industry is among the 15 largest in the world and second only to Brazil ($16bn) in Latin America. According…

Analysis

Joining forces: The public and private sectors are working together to develop medical tourism
OBG
plus

Competitive prices, proximity to high-potential markets and a number of hospitals recognised by the Joint Commission International are some of the factors that make Mexico a key player in the global medical tourism industry. According to the investment promotion agency ProMéxico, the segment has posted continuous growth for almost a decade, reaching an estimated $3.08bn in revenues in 2014, up 8% from $2.84bn in 2013, and nearly double the revenues reached in 2006 ($1.55bn). With its sights set…